Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.–Canadian multicenter study

Murphy, 2001, Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease, Ann Intern Med, 135, 17, 10.7326/0003-4819-135-1-200107030-00005 Cacoub, 2001, Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997, Clin Infect Dis, 32, 1207, 10.1086/319747 Lewden C, Héripret L, Bonnet F, Bévilacqua S, Jougla E, Boileau J, et al. Causes of death in HIV-infected adults in the era of Highly Active Antiretroviral Therapy (HAART), the French Survey “Mortalité 2000” [Abstract]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, 24-28 February 2002, Seattle, WA, abstract No. 753-W 2002. Bica, 2001, Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection, Clin Infect Dis, 32, 492, 10.1086/318501 Martin-Carbonero, 2001, Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients, AIDS Res Hum Retroviruses, 17, 1467, 10.1089/08892220152644160 Llovet, 2003, Hepatocellular carcinoma, Lancet, 362, 1907, 10.1016/S0140-6736(03)14964-1 El Serag, 1999, Rising incidence of hepatocellular carcinoma in the United States, N Engl J Med, 340, 745, 10.1056/NEJM199903113401001 El Serag, 2003, The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update, Ann Intern Med, 139, 817, 10.7326/0003-4819-139-10-200311180-00009 Benhamou, 1999, Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group, Hepatology, 30, 1054, 10.1002/hep.510300409 Bräu, 2006, Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy, J Hepatol, 44, 47, 10.1016/j.jhep.2005.07.006 Fattovich, 2004, Hepatocellular carcinoma in cirrhosis: incidence and risk factors, Gastroenterology, 127, S35, 10.1053/j.gastro.2004.09.014 Puoti, 2004, Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome, AIDS, 18, 2285, 10.1097/00002030-200411190-00009 Bruix, 2005, Management of hepatocellular carcinoma, Hepatology, 42, 1208, 10.1002/hep.20933 Llovet, 1999, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin Liver Dis, 19, 329, 10.1055/s-2007-1007122 United Network of Organ Sharing / Organ Procurement and Transplantation Network Policy 3.6.4.4 of November 18, 2005. Available at http://www.optn.org. Accessed September 11, 2006. Okuda, 1985, Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients, Cancer, 56, 918, 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E Kudo, 2003, Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score), J Gastroenterol, 38, 207, 10.1007/s005350300038 Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 2000; 31:840–45. Leung, 2002, Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients, Cancer, 94, 1760, 10.1002/cncr.10384 Chevret, 1999, A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire, J Hepatol, 31, 133, 10.1016/S0168-8278(99)80173-1 Marrero, 2005, Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort, Hepatology, 41, 707, 10.1002/hep.20636 Cillo, 2006, Prospective validation of the Barcelona Clinic Liver Cancer staging system, J Hepatol, 44, 723, 10.1016/j.jhep.2005.12.015 Pearson, 1908, The probable error of a mean, Biometrika, 6, 1, 10.1093/biomet/6.1.1 Mann, 1947, On a test of whether one of 2 random variables is stochastically larger than the other, Ann Math Stat, 18, 50, 10.1214/aoms/1177730491 Fisher, 1922, On the interpretation of Chi-square from contingency tables, and the calculation of P, J R Stat Soc, 85, 87, 10.2307/2340521 Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.2307/2281868 Cox, 1972, Regression models and life tables, J R Stat Soc Ser B, 34, 187 Garcia-Samaniego, 2001, Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C, Am J Gastroenterol, 96, 179, 10.1111/j.1572-0241.2001.03374.x El Serag, 2001, Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States, Hepatology, 33, 62, 10.1053/jhep.2001.21041 Stuart, 1996, Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival, Cancer, 77, 2217, 10.1002/(SICI)1097-0142(19960601)77:11<2217::AID-CNCR6>3.0.CO;2-M Lerose, 2001, Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease, Eur J Cancer, 37, 239, 10.1016/S0959-8049(00)00354-3 Hwang, 2004, Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma, World J Gastroenterol, 10, 2472, 10.3748/wjg.v10.i17.2472 Ryu, 2003, Thrombopoietin-producing hepatocellular carcinoma, Intern Med, 42, 730, 10.2169/internalmedicine.42.730 Zhang, 2004, Randomized controlled trial of screening for hepatocellular carcinoma, J Cancer Res Clin Oncol, 130, 417, 10.1007/s00432-004-0552-0 Sherman, 2001, Alphafetoprotein: an obituary, J Hepatol, 34, 603, 10.1016/S0168-8278(01)00025-3 Soto, 1997, Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis, J Hepatol, 26, 1, 10.1016/S0168-8278(97)80001-3 Darby, 1997, Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors’ Organisation, Lancet, 350, 1425, 10.1016/S0140-6736(97)05413-5